Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis

References

• Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(65-71):65.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563–608.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral Treatment of Adult HIV Infection Recommendations of the International AIDS Society — USA Panel. JAMA. 2010;304(3):321–333.
   PubMed Web of Science ®Google Scholar
• Squibb BM. FDA label for efavirenz capsules and tablets. November 2010. http://packageinsertsbmscom/pi/pi_sustivapdf. Accessed May 5, 2011..
   Google Scholar
• Pérez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trial. 2002;3(279-286):279.
   PubMedGoogle Scholar
• Das K, Bauman JD, Clark AD Jr, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA. 2008;105(5):1466–1471.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhan P, Li D, De CE, Liu X. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem. 2011;18:359–376.
   PubMed Web of Science ®Google Scholar
• Lansdon EB, Brendza KM, Hung M, et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem. 2010;53(10):4295–4299.
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718–727.
   PubMed Web of Science ®Google Scholar
• Janssen-Cilag International N.V. EDURANT 25 mg Film-Coated Tablets. Summary of Product Characteristics. August 2012. http://www.medicinesorguk/EMC/medicine/25490/SPC/Edurant+25+mg/. Accessed December 13, 2012..
   Google Scholar
• Janssen Products. EDURANT® (Rilpivirine). Full Prescribing Information. August 2012. http://www.edurant-infocom/sites/default/files/EDURANT-PI.pdf. Accessed December 13, 2012..
   Google Scholar
• Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 — a novel NNRTI — in treatment-naive HIV-1-infected subjects. AIDS. 2006;20:1721–1726.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55–65.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229–237.
   PubMed Web of Science ®Google Scholar
• Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.
   PubMed Web of Science ®Google Scholar
• Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012;28(5):437–446.
   PubMed Web of Science ®Google Scholar
• Hodder S, Arasteh K, de Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406–415.
   PubMed Web of Science ®Google Scholar
• Nelson M, Amaya G, Clumeck N, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother. 2012;67(8):2020–2028.
   PubMed Web of Science ®Google Scholar
• Cohen C, Wohl D, Arribas J, et al. STAR study: single-tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults. Paper presented at: 11th International Congress on Drug Therapy in HIV Infection; November 11–15, 2012; Glasgow, Scotland..
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64.
   PubMed Web of Science ®Google Scholar
• Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. Antimicrob Agents Chemother. 2012;56(8):4522–4524.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials; is blinding necessary? Control Clin Trials. 1996;17:1–12.
   PubMedGoogle Scholar
• Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669–677.
   PubMed Web of Science ®Google Scholar
• Fleiss J. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–145.
   PubMedGoogle Scholar
• Lau J, Ioannidis J, Schmid C. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–826.
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Rimsky L, Vingerhoets J, Eygen VV, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59(1):39–46.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients:pooled results from the Phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33–42.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81–91.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939–950.
   PubMed Web of Science ®Google Scholar
• Mills AM, Antinori A, Clotet B, et al. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naive, HIV-1-infected patients at 48 weeks. HIV Med. 2013;14(7):391–400.
   PubMed Web of Science ®Google Scholar
• Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis. AIDS. 2013;27(6):889–897.
   PubMed Web of Science ®Google Scholar
• Debyser Z, Pauwels R, Andries K, et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci USA. 1991;88(4):1451–1455.
   PubMed Web of Science ®Google Scholar
• Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40–47.
   PubMed Web of Science ®Google Scholar
• James C, Preininger L, Sweet M. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor. Am J Health Syst Pharm. 2012;69(10):857–861.
   PubMed Web of Science ®Google Scholar
• Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009;64(5):910–928.
   PubMed Web of Science ®Google Scholar
• HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Jan 10, 2011. http://www.aidsinfo.nih.gov/ContentFiles/Adult and Adolescent GL.pdf. Accessed June 22, 2011..
   Google Scholar
• Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75(11):4999–5008.
   PubMed Web of Science ®Google Scholar
• Schrijvers R, Desimmie BA, Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet. 2011;378(9787):201–203.
   PubMed Web of Science ®Google Scholar
• Maggi P, Montinaro V, Rusconi S, et al. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin Trials. 2014;15(3):87–91.
   PubMed Web of Science ®Google Scholar